Insulin remains to be a critical therapy for the management of diabetes despite of introduction of novel therapies. A basal and mealtime insulin is often required to achieve glucose control. Insulin is a critical therapy for type 2 diabetes:
Barriers to adherence include;6
Missed insulin doses are common, and an important factor in poor glycemic control. Mealtime doses are especially important, and are often omitted3
CeQur PAQ® a platform of simple, wearable, 3-day devices that have been developed to provide the benefits of newer, technologically advanced insulin therapies without their complexity and up-front expense. These devices have been designed to reduce the barriers and challenges of daily insulin injection therapy to enable people to achieve target glycemic control.
PAQ TOTAL is a wearable insulin delivery device that delivers up to 3 days of continuous pre-set basal insulin plus on- demand mealtime bolus in 2 unit increments.
PAQ TOTAL has two components:
To receive updates about this product, please join our mailing list, below.
Findings from two studies evaluating the company’s PAQ TOTAL™ Insulin Delivery Device among people with type 2 diabetes. The data demonstrate that the simple, three-day, wearable basal-bolus insulin delivery device significantly improved glycemic control among people with type 2 diabetes who transitioned to the device. Study participants also reported increased treatment satisfaction with the device as compared to insulin injections.
* Humalog® is a registered trademark of Eli Lilly and Company. NovoLog® is a registered trademark of Novo Nordisk A/S.